ONC BeOne Medicines Ltd.
P/E
--
Forward P/E
--
Price/Sales
--
Beta
--
Div Yield
--
Market Cap
--
Company Analysis
Latest News
BeOne Medicines' first quarter revenue jumped 35% to $1.51B on strong Brukinsa sales, leading to a raised FY26 forecast.
BeOne Medicines reported first quarter 2026 revenue of $1.51 billion, up 35% year-over-year, and non-GAAP diluted EPS of $3.24 per ADS. The results...
BeOne Medicines (BeiGene, Ltd.) Q1 2026 Earnings Preview: What Analysts Expect on May 06, 2026
Analysts expect BeOne Medicines (formerly BeiGene) to report Q1 2026 revenue of $1.45 billion and earnings per share of $0.85, with the stock currently trading...
BeOne Medicines' fourth quarter revenue of $1.5B beats estimates, driven by 38% growth in flagship drug BRUKINSA.
BeOne Medicines reported fourth quarter 2025 revenue of $1.5 billion, up 33% year-over-year, and non-GAAP diluted EPS of $1.95, beating analyst estimates. For...
BeiGene, Ltd. Reports Q4 2025 Earnings on February 26, 2026
BeiGene, Ltd. is projected to report Q4 2025 revenue of approximately $1.45 billion and earnings of $1.60 per share, with the stock currently trading at...